News 2025 - Appili Therapeutics

NEWS

Highlights

NEWS

NEWS 2024

November 13, 2025

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

November 5, 2025

Appili Therapeutics Announces Proposed Non-Brokered Private Placement

October 22, 2025

Appili Therapeutics to Attend BARDA Innovation Symposium 2025

October 1, 2025

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01

September 23, 2025

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

September 9, 2025

Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference

August 14, 2025

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026

August 6, 2025

Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine

June 25, 2025

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

May 30, 2025

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.

May 19, 2025

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

May 1, 2025

Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

April 28, 2025

Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™

April 2, 2025

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

March 18, 2025

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

February 14, 2025

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025